Abstract 1689TiP
Background
One of the unmet needs in Lung Cancer Care is the Stigma of patients due to the smoking habits; the condition of current smoker or former smoker causes the perception of the one’s incorrect lifestyle so, more than in other pathologies, patients with lung cancer are burdened with feelings of guilt and self-devaluation in anticipation of a negative social judgment. In addition to detecting this phenomenon, the study aims to psychologically support lung cancer patients, as well as smokers who belong to the Antismoking Centre in our Institute and who present with high levels of distress, through a psychotherapeutic path according to the EMDR (Eye Movement Desensitization and Reprocessing) model which could allow the reworking of traumatic or emotionally stressful moments, linked to the phases of the disease and to the personal history. The EMDR is one of the techniques that support smokers in quitting; the processing of the experience that occurs with EMDR allows the subject, through desensitization and cognitive restructuring, to change perspective and adopt more appropriate behaviors.
Trial design
Objectives of this study are the following: 1) to document the presence of stigma in current smokers or former smokers with lung cancer and subjects who undertake a smoke cessation program ; 2) to measure the correlation between stigma, level of anxiety, depression, quality of life and psychophysical well-being in the different phases of the disease starting from diagnosis and throughout treatment process;3) to investigate the impact and the efficacy of the EMDR model through the psychological re-evaluation of stress, depression and anxiety. The sociocultural, psychological factors and lifestyles of the participants will be investigated, including any gender-related differences regarding the Lung Cancer stigma, smoking habits and the outcome of a tobacco cessation process. A number of 45 subjects is planned to be recruited.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1617P - Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer
Presenter: Manish Kohli
Session: Poster session 11
1618P - Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Presenter: Anis Hamid
Session: Poster session 11
1619P - Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Presenter: Anna Kristiansen
Session: Poster session 11
1620P - Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Presenter: Sue Ingles
Session: Poster session 11
Resources:
Abstract
1621P - Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy
Presenter: Anders Bjartell
Session: Poster session 11
1622P - A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Presenter: Rahul Aggarwal
Session: Poster session 11
1623P - Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Alessio Crippa
Session: Poster session 11
1624P - Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study
Presenter: Martina Buffoni
Session: Poster session 11
1625P - Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study
Presenter: Yao Zhu
Session: Poster session 11